<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurol Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurol Genet</journal-id>
<journal-id journal-id-type="hwp">nng</journal-id>
<journal-id journal-id-type="publisher-id">NNG</journal-id>
<journal-title-group>
<journal-title>Neurology: Genetics</journal-title>
</journal-title-group>
<issn pub-type="epub">2376-7839</issn>
<publisher>
<publisher-name>Wolters Kluwer</publisher-name>
<publisher-loc>Baltimore</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29264390</article-id>
<article-id pub-id-type="pmc">5733249</article-id>
<article-id pub-id-type="publisher-id">NG2017005686</article-id>
<article-id pub-id-type="doi">10.1212/NXG.0000000000000198</article-id>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>60</subject>
<subject>61</subject>
<subject>77</subject>
<subject>97</subject>
<subject>228</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Characterization of a <italic>KCNB1</italic> variant associated with autism, intellectual disability, and epilepsy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Calhoun</surname>
<given-names>Jeffrey D.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="author-notes" rid="fn1">*</xref>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>(1) Dravet Syndrome Foundation, Postdoctoral research fellowship</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vanoye</surname>
<given-names>Carlos G.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="author-notes" rid="fn1">*</xref>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>Nanion technologies</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kok</surname>
<given-names>Fernando</given-names>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Editorial Advisory Board of Arquivos de Neuropsiquiatria</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>1. Methylmalonic acid determination by tandem mass spectrometry using stable isotope. Patent issued in 2009.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>Medical Director of Mendelics Genomic Analysis, a NGS lab, since 2013.</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>Speaker at NPC symposia from Actelion Pharmaceuticals</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>Commercial entity: Mendelics Genomic Analysis, Shareholder</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author">
<name>
<surname>George</surname>
<given-names>Alfred L.</given-names>
<suffix>Jr</suffix>
</name>
<degrees>MD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>Amgen, SAB for cardio-metabolic disorders</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for travel or speaker honoraria:</title>
<list-item>
<p>Praxis Precision Medicines, Inc. travel in 2016 to San Francisco to discuss licensing of lead compound with another company</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>Journal of Clinical Investigation, Editorial Consultant, 2001 - present Heart Rhythm Journal, Editorial Board, 2010-present Journal of General Physiology, Editorial Board, 2004-present</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>Merck Xenon Pharmaceuticals</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>NIH, NS0323287, PI NIH, HL122010, PI NIH, HL083374, PI NIH, HL131914, PI</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>Alternating Hemiplegia of Childhood Foundation Dravet Syndrome Foundation Simons Foundation St. Baldrick's Foundation</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License Fee Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kearney</surname>
<given-names>Jennifer A.</given-names>
</name>
<degrees>PhD</degrees>
<author-comment content-type="disclosure">
<p>
<list list-type="order">
<title>Scientific Advisory Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Gifts:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Funding for Travel or Speaker Honoraria:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Editorial Boards:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Patents:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Publishing Royalties:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Employment, Commercial Entity:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Consultancies:</title>
<list-item>
<p>(1) Praxis Precision Medicines</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Speakers' Bureaus:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Other Activities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Clinical Procedures or Imaging Studies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Commercial Entities:</title>
<list-item>
<p>(1) Sage Therapeutics (2) Xenon Pharmaceuticals, (3) Pairnomix LLC, (4) Ovid Therapeutics</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Government Entities:</title>
<list-item>
<p>(1) NINDS/NIH, R01-NS053792, 2005-2020</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Academic Entities:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Research Support, Foundations and Societies:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options/Board of Directors Compensation:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>License fee payments, Technology or Inventions:</title>
<list-item>
<p>(1) Dravet syndrome Mouse model, Xenon Pharmaceuticals, (2) Dravet syndrome Mouse model, Novartis, (3) Dravet syndrome Mouse model, Life Splice Technologies</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Royalty Payments, Technology or Inventions:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Research Sponsor:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
<p>
<list list-type="order">
<title>Legal Proceedings:</title>
<list-item>
<p>NONE</p>
</list-item>
</list>
</p>
</author-comment>
</contrib>
<aff>From the Department of Pharmacology (J.D.C., C.G.V., A.L.G., J.A.K.), Northwestern University Feinberg School of Medicine, Chicago, IL; Human Genome and Stem Cell Research Center (F.K.), Biosciences Institute, University of Sao Paulo, Brazil; and Mendelics Análise Genomica (F.K.), Sao Paulo, Brazil.</aff>
</contrib-group>
<author-notes>
<corresp>Correspondence to Dr. Kearney: <email>jennifer.kearney@northwestern.edu</email></corresp>
<fn id="fn1">
<label>*</label>
<p>These authors contributed equally to this work.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>Funding information and disclosures are provided at the end of the article. Go to <ext-link ext-link-type="uri" xlink:href="http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000198">Neurology.org/ng</ext-link> for full disclosure forms. The Article Processing Charge was funded by the NIH.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>11</day>
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="collection">
<month>12</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>11</day>
<month>12</month>
<year>2017</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>3</volume>
<issue>6</issue>
<elocation-id>e198</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>5</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>10</month>
<year>2017</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement>
<copyright-year>2017</copyright-year>
<copyright-holder>American Academy of Neurology</copyright-holder>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
</license>
</permissions>
<self-uri xlink:href="NG2017005686.pdf" xlink:title="pdf"></self-uri>
<abstract>
<sec>
<title>Objective:</title>
<p>To perform functional characterization of a potentially pathogenic <italic>KCNB1</italic> variant identified by clinical exome sequencing of a proband with a neurodevelopmental disorder that included epilepsy and centrotemporal spikes on EEG.</p>
</sec>
<sec>
<title>Methods:</title>
<p>Whole-exome sequencing identified the <italic>KCNB1</italic> variant c.595A&gt;T (p.Ile199Phe). Biochemical and electrophysiologic experiments were performed to determine whether this variant affected protein expression, trafficking, and channel functional properties.</p>
</sec>
<sec>
<title>Results:</title>
<p>Biochemical characterization of the variant suggested normal protein expression and trafficking. Functional characterization revealed biophysical channel defects in assembled homotetrameric and heterotetrameric channels.</p>
</sec>
<sec>
<title>Conclusions:</title>
<p>The identification of the <italic>KCNB1</italic> variant c.595A&gt;T (p.Ile199Phe) in a neurodevelopmental disorder that included epilepsy with centrotemporal spikes expands the phenotypic spectrum of epilepsies associated with <italic>KCNB1</italic> variants. The KCNB1-I199F variant exhibited partial loss of function relative to the wild-type channel. This defect is arguably less severe than previously reported <italic>KCNB1</italic> variants, suggesting the possibility that the degree of KCNB1 protein dysfunction may influence disease severity.</p>
</sec>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>OPEN-ACCESS</meta-name>
<meta-value>TRUE</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<p>De novo <italic>KCNB1</italic> variants have been identified in patients with early-infantile epileptic encephalopathy-26.<sup><xref ref-type="bibr" rid="R1">1</xref><xref ref-type="bibr" rid="R2">–</xref><xref ref-type="bibr" rid="R6">6</xref></sup> The <italic>KCNB1</italic> gene is intolerant of missense variation and is ranked among the top 1%–2% of intolerant genes in the genome (Z<sub>mis</sub> = 5.15).<sup><xref ref-type="bibr" rid="R7">7</xref></sup>
<italic>KCNB1</italic> encodes K<sub>V</sub>2.1, a voltage-gated potassium channel expressed in a wide variety of neuron types. K<sub>V</sub>2.1 channels underlie the principal delayed rectifier current in many neurons and contribute to regulation of neuronal excitability, especially during high-frequency firing.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> Characterization of previously reported <italic>KCNB1</italic> patient variants revealed a variety of functional defects, including loss of ion selectivity, reduced conductance, and dominant negative effects.<sup><xref ref-type="bibr" rid="R4">4</xref><xref ref-type="bibr" rid="R5">–</xref><xref ref-type="bibr" rid="R6">6</xref></sup></p>
<p>Here, we report a novel <italic>KCNB1</italic> variant in an individual with a neurodevelopmental disorder that included epilepsy and centrotemporal spikes on EEG. The proband exhibits infrequent seizures that are well controlled on sulthiame, intellectual disability, disruptive behavior, and autistic traits. Functional characterization revealed partial loss-of-function biophysical defects of assembled homotetrameric and heterotetrameric channels.</p>
<sec id="s1" sec-type="methods">
<title>METHODS</title>
<sec id="s1-1">
<title>Standard protocol approvals, registrations, and patient consents.</title>
<p>Anonymized genetic and clinical summaries were reported to us following clinical whole-exome sequencing. A review by the Northwestern University International Review Board deemed this study as exempt, nonhuman subject research. Consent for release of deidentified medical information was obtained by physicians in accordance with local institutional policies.</p>
</sec>
<sec id="s1-2">
<title>Plasmids and transfection.</title>
<p>I199F was introduced into a human K<sub>V</sub>2.1 cDNA clone pIRES2-DsRed-MST-K<sub>V</sub>2.1-WT.<sup><xref ref-type="bibr" rid="R6">6</xref></sup> Wild type (WT) and I199F were transiently expressed in CHO-K1 cells by electroporation (Maxcyte STX). Briefly, 7.5 μg of cDNA was mixed with 10 × 10<sup>6</sup> viable cells resuspended in 100 μL of electroporation buffer, transferred to a processing assembly (OC-100R10), and electroporated using the CHO protocol. Coexpression was achieved by coelectroporation with 5 μg each of pIRES2-DsRed-MST-K<sub>V</sub>2.1-I199F and pIRES2-eGFP-K<sub>V</sub>2.1-WT using the same protocol. Following electroporation, cells were incubated for 72 hours before experiments.</p>
</sec>
<sec id="s1-3">
<title>Cell-surface biotinylation.</title>
<p>Surface proteins on CHO-K1 cells expressing WT or mutant K<sub>V</sub>2.1 were labeled with membrane-impermeable Sulfo-NHS-Biotin (Thermo Fisher Scientific, Waltham, MA), as described.<sup><xref ref-type="bibr" rid="R6">6</xref></sup> Total and surface fractions were analyzed by immunoblotting using mouse anti-K<sub>V</sub>2.1 (1:250; K89/34; Neuromab, Davis, CA), mouse anti-transferrin receptor (TfR) (1:500; H68.4; Invitrogen, Carlsbad, CA), and rabbit anti-calnexin (1:250; H70; Santa Cruz, Dallas, TX) primary antibodies. AlexaFluor680 and 790-conjugated goat anti-rabbit and goat anti-mouse IgG secondary antibodies were used (1:20,000; Jackson ImmunoResearch, West Grove, PA). Blots were analyzed using the OdysseyCLx system and ImageStudio software (LI-COR). Calnexin immunoreactivity was absent from the cell-surface fraction, confirming the selectivity of biotin labeling for cell-surface proteins. Normalized total, surface, and total:surface ratios were compared using one-way analysis of variance.</p>
</sec>
<sec id="s1-4">
<title>Electrophysiology.</title>
<p>Automated planar-array patch-clamp recording was performed with the SyncroPatch 768 PE system (Nanion, München, Germany). Recording solutions are shown in <xref ref-type="table" rid="T1">table 1</xref>. Pulse generation was performed with PatchControl software (Nanion), and whole-cell currents were acquired at 5 kHz and filtered at 1 kHz. Currents were not leak subtracted. Fast and slow capacitances were compensated using internal algorithms within PatchControl software. Whole-cell currents were measured from a holding potential of −80 mV and elicited with depolarizing steps (500 milliseconds) from −80 to +60 mV (10 mV steps) followed by a step to 0 mV (tail currents, 250 milliseconds). Background currents were removed by digital subtraction of whole-cell currents recorded from nontransfected cells. To remove bias for expression efficiency or the functional level, homotetramer currents were analyzed from all cells with Rseal ≥0.5 GΩ, Rseries ≤20MΩ, and Cm &gt;2 pF. The peak current was normalized for cell capacitance and plotted against voltage to generate peak current density-voltage relationships. Voltage dependence of activation and inactivation were evaluated only from cells with positive outward current values following background subtraction. Tail currents measured 5 milliseconds after stepping to 0 mV were normalized to the largest tail current amplitude and plotted against the depolarizing test potential (−80 to +60 mV). Normalized G-V curves were fit with the Boltzmann function: G = 1/(1 + exp[(V − V<sub>½</sub>)/k]) to determine the voltage for half-maximal activation (V<sub>½</sub>) and slope factor (k). Voltage dependence of inactivation was assessed following a 5-second prepulse from −90 to +40 mV (10 mV steps) followed by a 250-millisecond step to +60 mV. Normalized peak currents measured at the +60 mV step were plotted against the prepulse voltage and fit with Boltzmann functions: I/I<sub>max</sub>= 1/(1 + exp[(V − V<sub>½</sub>)/k]) to determine the voltage for half-maximal inactivation (V<sub>½</sub>) and slope factor (k). For heteromeric (WT + I199F) channels, peak current density-voltage relationships and voltage dependence of channel activation and inactivation were evaluated from cells with positive outward current values after background subtraction. Outliers (&gt;±2 SDs) were not included. Results are expressed as mean ± SEM. <italic>p</italic> Values for comparisons between the mutant and WT (Student <italic>t</italic> test) are listed in <xref ref-type="table" rid="T2">table 2</xref> and in <xref ref-type="fig" rid="F1">figure</xref>.</p>
<table-wrap id="T1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Solutions for electrophysiologic recording</p>
</caption>
<graphic xlink:href="NG2017005686TT1"></graphic>
</table-wrap>
<table-wrap id="T2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<p>Biophysical channel properties of KCNB1-WT and KCNB1-I199F homotetramers and heterotetramers</p>
</caption>
<graphic xlink:href="NG2017005686TT2"></graphic>
</table-wrap>
<fig id="F1" orientation="portrait" position="float">
<label>Figure</label>
<caption>
<title>Functional characterization of KCNB1-WT and KCNB1-I199F</title>
<p>(A) Location of the I199F variant mapped onto the crystal structure of a K<sub>V</sub>2.1/K<sub>V</sub>1.2 chimera (PDB 29R9).<sup><xref ref-type="bibr" rid="R10">10</xref></sup> A channel tetramer is shown. I199F (magenta) lies in the S1 transmembrane segment of the voltage-sensing domain. (B) KCNB1-I199F is expressed and trafficked to the cell surface. Cell-surface expression was measured using cell-surface biotinylation of CHO-K1 cells transfected with wild-type (WT) or mutant K<sub>V</sub>2.1. Total (5 μg per lane) and surface fractions of K<sub>V</sub>2.1 were detected with the anti-K<sub>V</sub>2.1 antibody. Endogenous TfR levels were measured as a loading control. Calnexin was present in total cell lysates, but not surface fraction, demonstrating selective biotinylation of extracellular proteins. The blot shown is representative of 3 independent experiments. (C) Current-voltage relationships measured for KCNB1-I199F (n = 74) and WT homotetrameric channels (n = 185). (D) Voltage dependence of activation and inactivation curves calculated for KCNB1-I199F (n = 23) and WT (n = 63) homotetrameric channels. (E) Current-voltage relationships measured for KCNB1-I199F (n = 40) and WT (n = 27) heterotetrameric channels. (F) Voltage dependence of activation and inactivation curves calculated for KCNB1-I199F (n = 31) and WT (n = 26) heterotetrameric channels.</p>
</caption>
<graphic xlink:href="NG2017005686FF1"></graphic>
</fig>
</sec>
</sec>
<sec id="s2" sec-type="results">
<title>RESULTS</title>
<p>Clinical whole-exome sequencing was performed in an adolescent with intellectual disability, disruptive behavior, autistic features, epilepsy and centrotemporal spikes on EEG. Seizures are infrequent and well controlled with sulthiame. Exome sequencing revealed a single de novo missense variant in <italic>KCNB1</italic> c.595A&gt;T (p.Ile199Phe), which was confirmed by Sanger sequencing. This variant was absent in the ExAC and gnomAD databases containing exomes from 123,126 individuals unaffected by severe pediatric disease.<sup><xref ref-type="bibr" rid="R7">7</xref></sup> Isoleucine 199 is located in the S1 transmembrane segment of the voltage-sensing domain (<xref ref-type="fig" rid="F1">figure, A</xref>) and is evolutionarily invariant through chordates.</p>
<p>Effects of the KCNB1-I199F variant on channel function were evaluated following transient expression. CHO-K1 cells expressing KCNB1-I199F had total and cell-surface expression similar to the WT, indicating that channels were expressed and trafficked to the cell surface (<xref ref-type="fig" rid="F1">figure, B</xref>). KCNB1-I199F had a larger proportion of low-molecular-weight (MW) species relative to the WT in the total fraction (<xref ref-type="fig" rid="F1">figure, B</xref>). Kv2.1 undergoes extensive multisite phosphorylation that affects apparent MW and function.<sup><xref ref-type="bibr" rid="R8">8</xref></sup> However, there was no apparent MW difference in surface fractions, suggesting that mutant and WT channels at the cell surface have similar posttranslational modifications.</p>
<p>Automated planar patch-clamp recording in parallel of I199F and WT homomeric channels resulted in characteristic voltage-dependent potassium currents with outward rectification and late inactivation. The current-voltage relationship was similar between I199F and WT (<xref ref-type="fig" rid="F1">figure, C</xref>). I199F exhibited significant depolarizing shifts in the voltage dependence of activation and inactivation relative to the WT (<xref ref-type="fig" rid="F1">figure, D</xref>). To mimic the heterozygous condition, we coexpressed KCNB1-I199F plus WT. Coexpression of KCNB1-I199F with the WT trended toward decreased current amplitudes between −10 mV and 60 mV (<xref ref-type="fig" rid="F1">figure, E</xref>) (<italic>p</italic> = 0.104). Furthermore, there was a significant depolarizing shift in voltage dependence of activation relative to the WT alone, without affecting voltage dependence of inactivation (<xref ref-type="fig" rid="F1">figure, F</xref>). Details of the biophysical characterization are shown in <xref ref-type="table" rid="T2">table 2</xref>.</p>
</sec>
<sec id="s3" sec-type="discussion">
<title>DISCUSSION</title>
<p>The nature of channel dysfunction for KCNB1-I199F differs from previously reported <italic>KCNB1</italic> variants. I199F resulted in biophysical defects predicted to confer reduced channel availability due to shifts in the voltage dependence of activation, consistent with partial loss of function. By contrast, previously reported variants had complete loss of function, dominant negative effects, or loss of ion selectivity.<sup><xref ref-type="bibr" rid="R4">4</xref><xref ref-type="bibr" rid="R5">–</xref><xref ref-type="bibr" rid="R6">6</xref></sup> Previously characterized <italic>KCNB1</italic> variants were all located in the pore domain,<sup><xref ref-type="bibr" rid="R4">4</xref><xref ref-type="bibr" rid="R5">–</xref><xref ref-type="bibr" rid="R6">6</xref></sup> while I199F is the first reported variant located in the S1 transmembrane segment of the voltage-sensing domain. <italic>KCNB1</italic> variants have been reported in other voltage-sensing domain segments, but none have been functionally characterized to date.<sup><xref ref-type="bibr" rid="R3">3</xref></sup> However, variants in this domain of other voltage-gated potassium channels result in disease.<sup><xref ref-type="bibr" rid="R9">9</xref></sup> The I199F proband has neurodevelopmental and behavioral symptoms that are consistent with prior reports. However, seizures were reported to be infrequent and well controlled with sulthiame, whereas previously reported cases with pore variants had frequent, drug-resistant seizures.<sup><xref ref-type="bibr" rid="R1">1</xref>,<xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R4">4</xref><xref ref-type="bibr" rid="R5">–</xref><xref ref-type="bibr" rid="R6">6</xref></sup> This suggests the possibility that the variant type may influence the seizure phenotype and/or drug responsiveness. Consistent with this, a recent report suggests that the variant position (pore vs voltage sensor) influences the penetrance and severity of electroclinical and seizure phenotypes, while neurodevelopmental symptoms are present in all cases to date.<sup><xref ref-type="bibr" rid="R3">3</xref></sup> Larger cohorts with drug-response data will be necessary to investigate this link.</p>
<p>The phenotype spectrum associated with <italic>KCNB1</italic> variants will continue to expand as it becomes more widely screened. Correlating the clinical phenotype with channel dysfunction may provide insights into targeted therapeutic strategies.</p>
</sec>
</body>
<back>
<ack>
<title>ACKNOWLEDGMENT</title>
<p>The authors thank Katarina Fabre for technical support and the patient and family for their cooperation.</p>
</ack>
<sec sec-type="contributions">
<title>AUTHOR CONTRIBUTIONS</title>
<p content-type="contributions">Jeffrey D. Calhoun performed functional evaluation of the variant and wrote and edited the manuscript. Carlos G. Vanoye performed functional evaluation of the variant, performed statistical analysis of electrophysiology data, and edited the manuscript. Fernando Kok identified the <italic>KCNB1</italic> variant and edited the manuscript. Alfred L. George, Jr. conceived the study and edited the manuscript. Jennifer A. Kearney conceived the study, performed variant interpretation, and wrote and edited the manuscript.</p>
</sec>
<sec sec-type="funding">
<title>STUDY FUNDING</title>
<p content-type="funding">This work was supported by a grant from the NIH/National Institutes of Neurologic Disorders and Stroke to J.A.K. (R01 NS053792). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p>
</sec>
<sec sec-type="disclosure">
<title>DISCLOSURE</title>
<p content-type="disclosure">J.D. Calhoun receives fellowship support from the Dravet Syndrome Foundation. C.G. Vanoye consults for Nanion technologies. F. Kok has served on the editorial board of <italic>Arquivos de Neuropsiquiatria</italic>; holds a patent for Methylmalonic acid determination by tandem mass spectrometry using stable isotope; is an employee and shareholder of Mendelics Análise Genomica; and has been a speaker at NPC symposia from Actelion Pharmaceuticals. A.L. George, Jr. has served on a scientific advisory board of Amgen; has received travel funding from Praxis Precision Medicines, Inc.; has served on the editorial boards of <italic>the Journal of Clinical Investigation</italic>, <italic>Heart Rhythm Journal</italic>, and the <italic>Journal of General Physiology</italic>; is funded by the NIH, Merck Sharp &amp; Dohme, St. Baldrick's Foundation, AHC Foundation, and Simon's Foundation; received research support from Xenon Pharmaceuticals and Dravet syndrome foundation; and consulted for Gilead Sciences and Xenon Pharmaceuticals. J.A. Kearney is funded by the NIH and Ovid Therapeutics; consults for Praxis Precision Medicine; received research support from Sage Therapeutics, Xenon Pharmaceuticals, and Pairnomix, LLC; received license fee payments from Xenon Pharmaceuticals, Novartis, and Life Splice Technologies; and served on a scientific advisory board of Zogenix Inc. Go to <ext-link ext-link-type="uri" xlink:href="http://ng.neurology.org/lookup/doi/10.1212/NXG.0000000000000198">Neurology.org/ng</ext-link> for full disclosure forms.</p>
</sec>
<glossary>
<title>GLOSSARY</title>
<def-list>
<def-item>
<term id="G1">MW</term>
<def>
<p>molecular weight</p>
</def>
</def-item>
<def-item>
<term id="G2">WT</term>
<def>
<p>wild type</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>REFERENCES</title>
<ref id="R1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Allen</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Conroy</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shahwan</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>Unexplained early onset epileptic encephalopathy: exome screening and phenotype expansion</article-title>. <source/>Epilepsia
<year>2016</year>;<volume>57</volume>:<fpage>e12</fpage>–<lpage>e17</lpage>.<pub-id pub-id-type="pmid">26648591</pub-id></mixed-citation>
</ref>
<ref id="R2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Kovel</surname><given-names>CG</given-names></name>, <name name-style="western"><surname>Brilstra</surname><given-names>EH</given-names></name>, <name name-style="western"><surname>van Kempen</surname><given-names>MJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Targeted sequencing of 351 candidate genes for epileptic encephalopathy in a large cohort of patients</article-title>. <source/>Mol Genet Genomic Med
<year>2016</year>;<volume>4</volume>:<fpage>568</fpage>–<lpage>580</lpage>.<pub-id pub-id-type="pmid">27652284</pub-id></mixed-citation>
</ref>
<ref id="R3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Kovel</surname><given-names>CGF</given-names></name>, <name name-style="western"><surname>Syrbe</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Brilstra</surname><given-names>EH</given-names></name>, <etal>et al</etal></person-group>
<article-title>Neurodevelopmental disorders caused by de novo variants in KCNB1 genotypes and phenotypes</article-title>. <source/>JAMA Neurol
<year>2017</year>;<volume>74</volume>:<fpage>1228</fpage>–<lpage>1236</lpage>.<pub-id pub-id-type="pmid">28806457</pub-id></mixed-citation>
</ref>
<ref id="R4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saitsu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Akita</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tohyama</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>De novo KCNB1 mutations in infantile epilepsy inhibit repetitive neuronal firing</article-title>. <source/>Sci Rep
<year>2015</year>;<volume>5</volume>:<fpage>15199</fpage>.<pub-id pub-id-type="pmid">26477325</pub-id></mixed-citation>
</ref>
<ref id="R5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thiffault</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Speca</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Austin</surname><given-names>DC</given-names></name>, <etal>et al</etal></person-group>
<article-title>A novel epileptic encephalopathy mutation in KCNB1 disrupts Kv2.1 ion selectivity, expression, and localization</article-title>. <source/>J Gen Physiol
<year>2015</year>;<volume>146</volume>:<fpage>399</fpage>–<lpage>410</lpage>.<pub-id pub-id-type="pmid">26503721</pub-id></mixed-citation>
</ref>
<ref id="R6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torkamani</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bersell</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Jorge</surname><given-names>BS</given-names></name>, <etal>et al</etal></person-group>
<article-title>De novo KCNB1 mutations in epileptic encephalopathy</article-title>. <source/>Ann Neurol
<year>2014</year>;<volume>76</volume>:<fpage>529</fpage>–<lpage>540</lpage>.<pub-id pub-id-type="pmid">25164438</pub-id></mixed-citation>
</ref>
<ref id="R7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lek</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Karczewski</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Minikel</surname><given-names>EV</given-names></name>, <etal>et al</etal></person-group>
<article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title>. <source/>Nature
<year>2016</year>;<volume>536</volume>:<fpage>285</fpage>–<lpage>291</lpage>.<pub-id pub-id-type="pmid">27535533</pub-id></mixed-citation>
</ref>
<ref id="R8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohapatra</surname><given-names>DP</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Trimmer</surname><given-names>JS</given-names></name></person-group>
<article-title>Dynamic regulation of the voltage-gated Kv2.1 potassium channel by multisite phosphorylation</article-title>. <source/>Biochem Soc Trans
<year>2007</year>;<volume>35</volume>:<fpage>1064</fpage>–<lpage>1068</lpage>.<pub-id pub-id-type="pmid">17956280</pub-id></mixed-citation>
</ref>
<ref id="R9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jen</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Graves</surname><given-names>TD</given-names></name>, <name name-style="western"><surname>Hess</surname><given-names>EJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Primary episodic ataxias: diagnosis, pathogenesis and treatment</article-title>. <source/>Brain
<year>2007</year>;<volume>130</volume>:<fpage>2484</fpage>–<lpage>2493</lpage>.<pub-id pub-id-type="pmid">17575281</pub-id></mixed-citation>
</ref>
<ref id="R10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>SB</given-names></name>, <name name-style="western"><surname>Tao</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Campbell</surname><given-names>EB</given-names></name>, <etal>et al</etal></person-group>
<article-title>Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment</article-title>. <source/>Nature
<year>2007</year>;<volume>450</volume>:<fpage>376</fpage>–<lpage>382</lpage>.<pub-id pub-id-type="pmid">18004376</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>